7 years ago

Azeria Therapeutics Raises £4 Million for Hormone-Resistant Cancer Treatments

  • Azeria Therapeutics, a UK-based drug discovery company specializing in developing treatments for hormone-resistant breast and prostate cancer, has secured £4 million in Series A funding

  • The round was led by the CRT Pioneer Fund, managed by Sixth Element Capital LLP

  • Azeria is using its proprietary drug screening platform to develop a pipeline of small molecules targeting FOXA1, a crucial factor in the development of these cancers

  • The company plans to use the funding to continue developing its molecules, based on the research of Dr

  • Jason Carroll, an expert in pioneer factors in cancer at the Cancer Research UK Cambridge Institute.

      • ProblemHealthcare

      "Hormone-resistant breast and prostate cancers are hard to treat, and there are currently limited treatment options for patients. "

      Solution

      "Azeria Therapeutics is developing a pipeline of small molecules designed to selectively inhibit pioneer factors, which are essential for the development and maintenance of hormone-resistant cancers. "

      Covered on